NPPB and cancer: Besides adverse events e.g., myocarditis, arrhythmia and vascular toxicity (e.g. myocardial infarction or stroke) also mild entities including cancer-therapy related cardiac dysfunction (CTRCD) characterized by increase in cardiac biomarkers (troponin or N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) or decrease in left ventricular ejection fraction (LV-EF) and global longitudinal strain (LV GLS) are included [9].